Inventiva (NASDAQ:IVA) Stock Price Up 3.2% – What’s Next?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) traded up 3.2% during trading on Monday . The stock traded as high as $4.64 and last traded at $4.6250. 18,199 shares were traded during trading, a decline of 80% from the average session volume of 90,330 shares. The stock had previously closed at $4.48.

Analyst Upgrades and Downgrades

IVA has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 target price on shares of Inventiva in a research report on Tuesday, September 30th. Wall Street Zen raised Inventiva to a “hold” rating in a research report on Saturday, October 18th. HC Wainwright lifted their price objective on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Finally, Guggenheim lowered their target price on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Inventiva currently has a consensus rating of “Moderate Buy” and an average price target of $17.33.

Inventiva Stock Up 2.1%

The stock’s fifty day moving average price is $4.43 and its 200 day moving average price is $4.38.

Institutional Investors Weigh In On Inventiva

A number of hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC bought a new position in shares of Inventiva during the 3rd quarter valued at $116,000. Millennium Management LLC bought a new stake in Inventiva in the third quarter worth $649,000. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Inventiva by 55.6% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after buying an additional 9,212 shares during the period. Finally, Creative Planning purchased a new stake in Inventiva during the 2nd quarter valued at about $32,000. 19.06% of the stock is currently owned by institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.